维拉帕米预防ERCP后急性胰腺炎的实验研究

目的　探讨维拉帕米预防ERCP术后急性胰腺炎发生的疗效及机制。方法　建立假手术 (S组 )、ERCP组 (E组 )和维拉帕米预防组 (V组 ) ,比较各组急性胰腺炎发生率、血清IL - 6、淀粉酶和胰腺组织磷脂酶A2 (PLA2 )的活性。结果　E组并发急性胰腺炎 2例 (10 .0 % ,2 /2 0 ) ,明显高于V组和S组 (0 .0 % ,0 /2 0 )(P <0 .0 5 )。E组大鼠血清IL - 6、淀粉酶和胰腺组PLA2 的活性明显高于V组和S组 (P <0 .0 5 )。结论　钙通道阻滞剂维拉帕米能降低ERCP后急性胰腺炎的发生率 ,可能是通过抑制胰腺组织PLA2 的活化来实现的。

Experimental study of verapamil therapy for prevention of acute pancreatitis after ERCP

Objective:To explore the effect of verapamil therapy for prevention of acute pancreatitis after ERCP.Methods:Three groups were set including sham group(group S), ERCP group(group E) and verapamil group(group V). The occurrence rates of acute pancreatitis in the three groups were recorded.The venous blood samples were drawn 24 hours after operation for testing amylase and interleukin-6 (IL-6). Meanwhile the samples of pancreatic tissue were taken for studying the activity of PLA2.Results:The values of amylase and IL-6 in group V were significantly lower than those in group E (P<0.05). The activity of PLA 2 in group V was significantly weaker than that in group E (P<0.05). The occurrence rate of acute pancreatitis in group V was significantly lower than that in group E (P<0.05).Conclusion:Verapamil therapy may prevent those who undergo ERCP from acute pancreatitis by the activity of PLA 2.